Title of seminar: Hepatocyte stem cells as cell replacement therapy for liver disease

Bruce Wang, MD, is an Assistant Professor at Department of Medicine, Division of Gastroenterology, UCSF. The long-term goals of Bruce’s lab are to improve the understanding of liver disease pathophysiology and develop novel methods of treatment for liver diseases, including cell replacement therapy. Currently, we have two major research focuses: 1) understanding the biology of adult hepatocyte stem cells and 2) developing a liver cell atlas.

Bruce was born in China and grew up in the San Francisco Bay Area. He went to college at Stanford and did his medical school, residency and fellowship at UCSF. After a postdoctoral fellowship at Stanford, he came back to UCSF to start his lab. He enjoys exploring and photographing the Bay Area outdoors with his wife and two young sons.

Title of seminar: Stem Cells and Genomics for Precision Medicine

Joseph C. Wu, MD, PhD is Director of the Stanford Cardiovascular Institute and Simon H. Stertzer Professor of Medicine (Cardiology) and Radiology at the Stanford School of Medicine. Dr. Wu received his MD from Yale University School of Medicine. He trained in internal medicine and cardiology at UCLA followed by a PhD in the Dept of Molecular Pharmacology.

Dr. Wu has received numerous awards, including National Institutes of Health (NIH) Director’s New Innovator Award (2008), NIH Roadmap Transformative Award (2009), American Heart Association (AHA) Innovative Research Award (2009), Presidential Early Career Award for Scientists and Engineers given out by President Obama (2010), AHA Established Investigator Award (2012), Burroughs Wellcome Foundation Innovation in Regulatory Science Award (2015), and AHA Merit Award (2017). He received the Best Basic Science Manuscript Award in Circulation (2006 & 2014), Best Manuscript Award in Circulation Research (2013 & 2017), and the William Parmley outstanding paper award in JACC (2009 & 2017). He also received the inaugural AHA Joseph A. Vita Award (2015) which is given to an investigator whose body of work published in the last 5 years has had transformative impact on basic, translational, or clinical cardiovascular research. Dr. Wu currently serves on the Scientific Advisory Board for the Keystone Symposia (2014-2020), FDA Cellular, Tissue, and Gene Therapies Advisory Committee (2017-2020), AHA National Board of Directors (2017-2019), and Chair of the AHA National Research Committee (2017-2019).